Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease

Minerva Urologica e Nefrologica

Volumn 54, Issue 2, 2002, Pages 65-79

  Guan, Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder diseases, physiopathology; Kidney disease, physiopathology; Prostate, physiopathology; Receptors, cytoplasmic and nuclear; Transcriptional factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CELL RECEPTOR; FATTY ACID; ISOPROTEIN; PEROXISOME PROLIFERATOR; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR;

BLADDER; BLADDER CARCINOMA; BLADDER TUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DIABETIC NEPHROPATHY; FATTY ACID METABOLISM; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INTERSTITIUM; KIDNEY PROXIMAL TUBULE; KIDNEY TUMOR; LIPID METABOLISM; NEPHRON; PROSTATE CARCINOMA; PROSTATE TUMOR; REVIEW; SODIUM TRANSPORT; URETER; URINARY TRACT DISEASE; WATER TRANSPORT; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DIMERIZATION; DIURESIS; DRUG EFFECT; FAT INTAKE; FEMALE; GENE EXPRESSION REGULATION; KIDNEY CIRCULATION; MALE; METABOLISM; NATRIURESIS; PHYSIOLOGY; URINARY TRACT; URINARY TRACT CANCER; UROTHELIUM;

ANIMAL; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; DIABETIC NEPHROPATHIES; DIETARY FATS; DIMERIZATION; DIURESIS; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; LIPIDS; MALE; NATRIURESIS; ORGAN SPECIFICITY; PEROXISOME PROLIFERATORS; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RENAL CIRCULATION; TRANSCRIPTION FACTORS; URINARY TRACT; UROLOGIC DISEASES; UROLOGIC NEOPLASMS; UROTHELIUM; ANIMALS; HUMANS; LIPID METABOLISM; RETINOID X RECEPTORS;

EID: 0035997309     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Peroxisome proliferator-activated receptor: Nuclear control of metabolism
2. Peroxisome proliferator-activated receptor-γ: From adipogenesis to carcinogenesis
3. Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
4. Peroxisome proliferator-activated receptor γ and metabolic disease
5. Mechanism of action of fibrates on lipid and lipoprotein metabolism
6. Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond
7. Activation of PPAR-δ alters lipid metabolism in db/db mice
8. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
9. Differential expression of the peroxisome proliferator-activated receptor γ (PPAR-γ) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse
10. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
11. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
12. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
13. The organization, promoter analysis, and expression of the human PPAR-γ gene
14. PPARg 3 mRNA: A distinct PPAR-γ mRNA subtype transcribed from an independent promoter
15. The nuclear receptor ligand-binding domain: Structure and function
16. The PPARs: From orphan receptors to drug discovery
17. 4 pathway to inflammation control
18. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
19. Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
20. 12-14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPAR-γ
21. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ
22. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
23. Peroxisome proliferator-activated receptors, coactivators, and downstream targets
24. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferatoractivated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM patients
25. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissure distribution but different responsiveness to PPAR activators
26. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643
27. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α
28. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
29. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
30. A critical role for the peroxisome proliferator-activated receptor α (PPAR-α) in the cellular fasting response: The PPAR-α-null mouse as a model of fatty acid oxidation disorders
31. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis
32. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal β-oxidation, PPAR-α, and steatohepatitis
33. Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
34. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
35. Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism
36. Expression of putative fatty acid transporter gene are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner
37. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with age-dependent cardiac toxicity
38. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes
39. Reactivation of peroxisome proliferator-activated receptor α is associated with contractile dysfunction in hypertrophied rat heart
40. Hypoxia in vivo decreases peroxisome proliferator-activated receptor α-regulated gene expression in rat heart
41. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR-delta
42. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
43. Cloning and function of rabbit peroxisome proliferator-activated receptor δ/β in mature osteoclasts
44. Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: A possible role of these receptors in negative regulation of mast cell activation
45. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor δ/β
46. Critical roles of PPAR-δ/β in keratinocyte response to inflammation
47. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPAR-α mutant mice
48. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer
49. Genetic disruption of PPAR-δ decreases the tumorigenicity of human colon cancer cells
50. PPAR-δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs
51. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
52. PPAR-γ an essential regulator of adipogenesis and modulator of fat cell function
53. Differential activation of adipogenesis by multiple PPAR isoforms
54. A dominant-negative peroxisome proliferator-activated receptor γ (PPAR-γ) mutant is a constitutive repressor and inhibits PPAR-γ-mediated adipogenesis
55. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro
56. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
57. A Pro12Ala substitution in PPAR-γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
58. New drug targets for type 2 diabetes and the metabolic syndrome
59. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
60. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency
61. PPAR-γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
62. Inhibition of RXR and PPAR-γ ameliorates diet-induced obesity and type 2 diabetes
63. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ
64. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans
65. The hormone resistin links obesity to diabetes
66. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
67. Induction of adipocyte complement-related protein of 30 KD by PPAR-γ agonists: A potential mechanism of insulin sensitization
68. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
69. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
70. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
71. A PPAR-γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
72. PPARγ agonists inhibit production of monocyte inflammatory cytokines
73. Expression of the peroxisome proliferator-activated receptor γ (PPAR-γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
74. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
75. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging
76. Activation of proliferator-activator receptors α and γ induces apoptosis of human monocyte-derived macrophages
77. Expression and function of PPAR-γ in rat and human vascular smooth muscle cells
78. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
79. Peroxisomal proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells
80. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: Effect of PPAR-γ activation on abnormal lipid metabolism in liver of Zucker fatty rats
81. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
82. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
83. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
84. Expression of peroxisome proliferator-activated receptor γ (PPAR-γ) in human transitional bladder cancer and its role in inducing cell death
85. Terminal differentiation of human breast cancer through PPARγ
86. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
87. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer in vitro and in BNX mice
88. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis
89. Peroxisome proliferator-activated receptors: Roles in tumorigenesis and chemoprevention in human cancer
90. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2
91. Control of vascular cell proliferation and migration by PPAR-γ: A new approach to the macrovascular complications of diabetes
92. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells
93. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR-γ 2 versus PPARγ 1 and activation with retinoid X receptor agonists and antagonists
94. Differential expression of peroxisome proliferator-activated receptors (PPARs):tissue distribution of PPAR-α, β, and -γ in the adult rat
95. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
96. Peroxisome proliferator-activated receptor γ1 (PPAR-γ1) expresses in rat mesangial cells and PPAR-γ agonists modulate its differentiation
97. Advanced glycation end product-induced peroxisome proliferator-activated receptor γ gene expression in the cultured mesangial cells
98. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature
99. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells
100. Upregulation of type I collagen by TGF-α in mesangial cells is blocked by PPAR-β activation
101. Hypertonic stress induces COX2 dependent prostacyclin synthesis in renal medullary interstitial cell (RMICs) and down-stream activation of PPAR-δ dependent survival mechanism
102. Peroxisome proliferator-activated receptor-γ expression in human malignant and normal brain, breast and prostate-derived cells
103. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells
104. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer
105. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
106. Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma
107. Dietary lipids regulate β-oxidation enzyme gene expression in the developing rat kidney
108. Role of peroxisome proliferator-activated receptor-α in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding
109. Etomoxir-induced PPAR-α-modulated enzymes protect during acute renal failure
110. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation
111. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase
112. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats
113. Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding
114. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats
115. Clinical evaluation of a new oral hypoglycemic agent CS-045 in patients with non-insulindependent diabetes mellitus poorly controlled by sulphonylureas: A dose-finding by dose increasing method
116. Significant weight gain with Rezulin therapy
117. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats
118. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
119. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
120. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
121. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist troglitazone (TGL) protects against non-diabetic glomerulosclerosis
122. The peroxisome proliferator-activated receptor (PPAR) γ agonist troglitazone increases MCP-1 expression in experimental glomerulonephritis
123. Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists
124. Role of peroxisome proliferator-activated receptor γ and its ligands in non-neoplastic and neoplastic human urothelial cells
125. Peroxisome proliferator-activated receptor-γ expression in human malignant and normal brain, breast and prostate-derived cells
126. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells
127. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer
128. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
129. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-delta12, 14-prostaglandin J2
130. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
131. Peroxisome proliferator-activated receptor α is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma